CRVS | Corvus Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	7.94 - 9.37
52 Week Range	1.2300 - 9.37
Beta	1.36
Implied Volatility	179.92%
IV Rank	49.38%
Day's Volume	1,381,997
Average Volume	592,935
Shares Outstanding	62,551,300
Market Cap	564,212,726
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-03-23

Valuation
Profitability
Growth
Health
P/E Ratio	-20.98
Forward P/E Ratio	N/A
EPS	-0.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	28
Country	USA
Website	CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

CRVS's peers: ABUS, ADAP, AFMD, APTO, BCLI, CANF, CRIS, MREO, TERN, PDSB, INZY, HOOK, XFOR, DAWN, ABOS, ENLV, EVGN, MBIO, MTNB, NCNA, ORMP, PGEN, PIRS, PLX, PYXS, RANI, SLRX, TLSA, TNYA

*Chart delayed

Analyzing fundamentals for CRVS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see CRVS Fundamentals page.

Watching at CRVS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CRVS Technicals page.